ReportGem ReportGem

GLOBAL RESEARCH ARCHIVE

アステラス製薬 (4503) 1Q’26決算: 通期でコアOPマージン30%の達成が期待できる力強いスタート

Published: 2026-08-05Institution: JPMorganCompany / ticker: 4503.TPages: 12Original language: 日语
4503.T coverageJPMorgan research

Research evidence excerpt

The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.

The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.

Open report viewer

Related research and intelligence

アステラス製薬: F3/27 Q1決算：高水準なスタート。2Q以降はコスト消化も加速予定2026-08-05 · Morgan StanleyAstellas Pharma (4503) 1Q FY2026 results: Strong start that should lead to full-year core operating margin reaching 30%2026-08-05 · JPMorganSmartStop Good Expense Trends Help Drive 2Q FFO Upside and Guidance Increase2026-08-05 · JPMorganCushman & Wakefield 2Q Top Line/EBITDA Beat, Guidance Raised; Strong Leasing Offset Particularly Weak Capital Markets2026-08-05 · JPMorganUnicharm (8113) 2Q results: Watching specific measures on price pass-through and likelihood from 3Q onward2026-08-05 · JPMorganOil and Natural Gas Corporation 1Q: In-line EBITDA driven by higher oil prices; volumes weak2026-08-05 · JPMorgan